Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 1 13Phase NA 7Phase 3 4Phase 1/2 4Phase 2/3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 20Thoracic 7Gynecologic 6Lymphoid 5Other hematologic neoplasm 3Head & Neck 3Breast 3Sarcoma 2Other solid neoplasm 2Genitourinary 2Dermatologic 2CNS 1

Conditions

Glioblastoma 1

Interventions

Temozolomide 11Lomustine 6Radiotherapy 4Magnetic Resonance Spectroscopy 3Etoposide 3Carboplatin 3Bevacizumab 3vocimagene amiretrorepvec 2Vincristine 2Radiation 2Gefitinib 2veliparib 1trofosfamide 1trametinib 1tozuleristide 1tinostamustine 1regorafenib 1omburtamab I-131 1entrectinib 1dabrafenib 1cobimetinib 1carbon-11 acetate 1capmatinib 1antisecretory factor 1alectinib 1Vorinostat 1Vemurafenib 1Thiotepa 1Sunitinib 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Drug Therapy × CNS × Clear all
NCT03008148 2021-05-11

Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM

Johnpro Biotech, Inc.

Phase 2/3 Unknown
288 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡